Cardiva has decided to buy shares in one of the most important regenerative medicine and cell therapy companies in Spain, to continue strengthening its business and expansion
Cardiva is strengthening its position as one of the leading companies in the field of medical device manufacturing and distribution, thanks to its recently acquired shares in Histocell, a Bilbao-based biopharmaceutical company which is at the forefront of regenerative medicine and cell therapy in Spain. This step is part of Cardiva’s expansion and business diversification plan.
Ignacio Vega, CEO of Cardiva, said that “thanks to the ongoing research carried out by Histocell to develop new techniques and products, it is an important innovation hub with great growth potential”. “Advanced therapies are a burgeoning field with great prospects,” he added. “This partnership with Histocell enables us to share knowledge in order to offer a better and more comprehensive service every day to healthcare professionals, and innovative solutions to patients all over the world”.
Thanks to this partnership, Cardiva will be able to break into the world of regenerative medicine and cell therapy, to contribute to the development of this field with its expertise. According to Mr Vega, “Histocell has a varied portfolio which enables it to diversify risk, with products in different stages of development, from design to sales. Being a shareholder of Histocell will help Cardiva to grow and optimise our financial forecasts”.
“With Cardiva on board we have gained a new industrial partner in the field of healthcare. This strengthens our company’s position in this area, as we aim to offer the market innovative medical devices and drugs that help to improve patients’ quality of life,” said Julio Font, CEO of Histocell.
One of Histocell’s main programmes includes phase II clinical trials with cell therapy drugs to treat diseases caused by oxidative stress and to regenerate bones, and the development and manufacturing of medical and cosmetic devices for the treatment of ulcers and advanced dermatology. Histocell has units to manufacture both its own and third parties’ cell therapy drugs and medical devices certified by the Spanish Agency of Medicines (AEMPS).
Cardiva is a Spanish company that manufactures and markets a wide range of medical products worldwide. Innovation, through collaboration with healthcare professionals, has been its priority for more than 30 years, with the aim of improving the quality of patients’ lives and fostering the sustainability of healthcare systems.
Further information at cardiva.com/.
Histocell is a biopharmaceutical company focused on the development of novel medical devices and cell therapy drugs for regenerative medicine. It has a highly qualified team of 30 specialists and production facilities certified by the Spanish Agency of Medicines (AEMPS) to manufacture cell therapy drugs.
Some of its main programmes include:
- Development of cell therapy drugs based on the proprietary cell platform HC016 to treat diseases caused by oxidative stress (acute spinal cord injury, acute lung injury and critical limb ischaemia in lower extremities), and Bonecure for bone regeneration. Both these drugs are in phase II of a clinical trial with patients.
- Development of patent-protected medical devices to treat various diseases such as chronic ulcers, bone and cartilage defects, oral mucosa lesions, etc.
- Medical components and devices for facial and hair cosmetics.
- GMP production of products for cell therapy for third parties.
Further information at histocell.com.